# A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma

> **NCT00215956** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 31 (actual)

## Conditions studied

- Rectal Neoplasms

## Interventions

- **DRUG:** topotecan
- **PROCEDURE:** radiation
- **PROCEDURE:** surgery

## Key facts

- **NCT ID:** NCT00215956
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2013-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00215956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00215956, "A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00215956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*